Inactive Ingredient Search for Approved Drug Products

About this Database | Back to Search Page

SRS | Guidances | CFR

You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with A

	Quarter	Inactive Ingredient	Route of Administration	Dosage Form	Maximum Potency per unit dose	Maximum Daily Exposure	Status
40	Q3 2021	ACACIA	ORAL	POWDER	1231.00 mg		Correction
40	Q4 2021	ACACIA	ORAL	POWDER	800.00 mg		Correction
137	Q4 2021	ACRYLATES COPOLYMER	TOPICAL	SOLUTION	5.40 %w/w		Correction
331	Q4 2021	ANHYDROUS CITRIC ACID	BUCCAL	FILM, SOLUBLE		3 mg	Correction
42	Q3 2021	ACACIA	ORAL	POWDER, FOR SUSPENSION	648.00 mg		MDE Replacement
42	Q4 2021	ACACIA	ORAL	POWDER, FOR SUSPENSION		7386 mg	MDE Replacement
57	Q3 2021	ACESULFAME	ORAL	SOLUTION	4.00 mg/ 1.00 ml		MDE Replacement
57	Q4 2021	ACESULFAME	ORAL	SOLUTION		120 mg	MDE Replacement
64	Q3 2021	ACESULFAME POTASSIUM	ORAL	SOLUTION	200.00 mg		MDE Replacement
64	Q4 2021	ACESULFAME POTASSIUM	ORAL	SOLUTION		288 mg	MDE Replacement
66	Q3 2021	ACESULFAME POTASSIUM	ORAL	TABLET	27.80 mg		MDE Replacement
66	Q4 2021	ACESULFAME POTASSIUM	ORAL	TABLET		111.2 mg	MDE Replacement
70	Q3 2021	ACESULFAME POTASSIUM	ORAL	TABLET, FOR SUSPENSION	1.80 mg		MDE Replacement
70	Q4 2021	ACESULFAME POTASSIUM	ORAL	TABLET, FOR SUSPENSION		7.2 mg	MDE Replacement
128	Q3 2021	ACRYL-EZE 93018509 WHITE	ORAL	TABLET	76.68 mg		MDE Replacement
128	Q4 2021	ACRYL-EZE 93018509 WHITE	ORAL	TABLET		153.36 mg	MDE Replacement
159	Q3 2021	ALCOHOL	INTRAMUSCULAR	INJECTION	20.00 %w/v		MDE Replacement
159	Q4 2021	ALCOHOL	INTRAMUSCULAR	INJECTION		1000 mg	MDE Replacement
164	Q3 2021	ALCOHOL	INTRAVENOUS	INJECTION, EMULSION	2.85 %w/v		MDE Replacement
164	Q4 2021	ALCOHOL	INTRAVENOUS	INJECTION, EMULSION		520 mg	MDE Replacement
183	Q3 2021	ALCOHOL	ORAL	SUSPENSION	72.50 mg		MDE Replacement
183	Q4 2021	ALCOHOL	ORAL	SUSPENSION		520 mg	MDE Replacement
185	Q3 2021	ALCOHOL	ORAL	SYRUP	81.30 mg/ 1.00 ml		MDE Replacement
185	Q4 2021	ALCOHOL	ORAL	SYRUP		21000 mg	MDE Replacement
193	Q3 2021	ALCOHOL	SUBLINGUAL	SPRAY	49.60 mg/ 1.00 ml		MDE Replacement
193	Q4 2021	ALCOHOL	SUBLINGUAL	SPRAY		396.8 mg	MDE Replacement
198	Q3 2021	ALCOHOL	TOPICAL	GEL, METERED	72.60 %w/w		MDE Replacement
198	Q4 2021	ALCOHOL	TOPICAL	GEL, METERED		525 mg	MDE Replacement
237	Q3 2021	ALUMINUM POLYESTER	TRANSDERMAL	FILM, EXTENDED RELEASE	81.00 mg		MDE Replacement
237	Q4 2021	ALUMINUM POLYESTER	TRANSDERMAL	FILM, EXTENDED RELEASE		81 mg	MDE Replacement
240	Q3 2021	ALUMINUM SILICATE	ORAL	TABLET, EXTENDED RELEASE	94.00 mg		MDE Replacement
240	Q4 2021	ALUMINUM SILICATE	ORAL	TABLET, EXTENDED RELEASE		94 mg	MDE Replacement
242	Q3 2021	ALUMINUM SILICATE	TOPICAL	SYSTEM	18.90 mg		MDE Replacement
242	Q4 2021	ALUMINUM SILICATE	TOPICAL	SYSTEM		18.9 mg	MDE Replacement
245	Q3 2021	ALUMINUM STEARATE	ORAL	CAPSULE, EXTENDED RELEASE	0.40 mg		MDE Replacement
245	Q4 2021	ALUMINUM STEARATE	ORAL	CAPSULE, EXTENDED RELEASE		0.8 mg	MDE Replacement
246	Q3 2021	ALUMINUM STEARATE	ORAL	TABLET	2.80 mg		MDE Replacement
246	Q4 2021	ALUMINUM STEARATE	ORAL	TABLET		5.6 mg	MDE Replacement
287	Q3 2021	AMMONIA SOLUTION	ORAL	TABLET, EXTENDED RELEASE	NA		MDE Replacement
287	Q4 2021	AMMONIA SOLUTION	ORAL	TABLET, EXTENDED RELEASE		5.9 mg	MDE Replacement
296	Q3 2021	AMMONIO METHACRYLATE COPOLYMER TYPE A	ORAL	CAPSULE, EXTENDED RELEASE	42.40 mg		MDE Replacement
296	Q4 2021	AMMONIO METHACRYLATE COPOLYMER TYPE A	ORAL	CAPSULE, EXTENDED RELEASE		63.6 mg	MDE Replacement
300	Q3 2021	AMMONIO METHACRYLATE COPOLYMER TYPE B	ORAL	CAPSULE	109.56 mg		MDE Replacement
300	Q4 2021	AMMONIO METHACRYLATE COPOLYMER TYPE B	ORAL	CAPSULE		219.12 mg	MDE Replacement
301	Q3 2021	AMMONIO METHACRYLATE COPOLYMER TYPE B	ORAL	CAPSULE, EXTENDED RELEASE	91.88 mg		MDE Replacement
301	Q4 2021	AMMONIO METHACRYLATE COPOLYMER TYPE B	ORAL	CAPSULE, EXTENDED RELEASE		178.34 mg	MDE Replacement
305	Q3 2021	AMMONIO METHACRYLATE COPOLYMER TYPE B	ORAL	TABLET, FILM COATED	8.00 mg		MDE Replacement
305	Q4 2021	AMMONIO METHACRYLATE COPOLYMER TYPE B	ORAL	TABLET, FILM COATED		32 mg	MDE Replacement
311	Q3 2021	AMMONIUM CHLORIDE	ORAL	TABLET	4.20 mg		MDE Replacement
311	Q4 2021	AMMONIUM CHLORIDE	ORAL	TABLET		8.4 mg	MDE Replacement
328	Q3 2021	ANHYDROUS CITRIC ACID	INTRACARDIAC	INJECTION	0.25 %w/v		MDE Replacement
328	Q4 2021	ANHYDROUS CITRIC ACID	INTRACARDIAC	INJECTION		22.5 mg	MDE Replacement
329	Q3 2021	ANHYDROUS CITRIC ACID	INTRAMUSCULAR	INJECTION	0.33 %w/v		MDE Replacement
329	Q4 2021	ANHYDROUS CITRIC ACID	INTRAMUSCULAR	INJECTION		22.5 mg	MDE Replacement
332	Q3 2021	ANHYDROUS CITRIC ACID	INTRAVENOUS	INJECTION	166.00 mg		MDE Replacement
332	Q4 2021	ANHYDROUS CITRIC ACID	INTRAVENOUS	INJECTION		510 mg	MDE Replacement
346	Q3 2021	ANHYDROUS CITRIC ACID	ORAL	GRANULE, FOR SUSPENSION	4.90 mg		MDE Replacement
346	Q4 2021	ANHYDROUS CITRIC ACID	ORAL	GRANULE, FOR SUSPENSION		29.4 mg	MDE Replacement
359	Q3 2021	ANHYDROUS CITRIC ACID	ORAL	TABLET, CHEWABLE, EXTENDED RELEASE	8.00 mg		MDE Replacement
359	Q4 2021	ANHYDROUS CITRIC ACID	ORAL	TABLET, CHEWABLE, EXTENDED RELEASE		12 mg	MDE Replacement
366	Q3 2021	ANHYDROUS CITRIC ACID	SUBCUTANEOUS	INJECTION	0.25 %w/v		MDE Replacement
366	Q4 2021	ANHYDROUS CITRIC ACID	SUBCUTANEOUS	INJECTION		22.5 mg	MDE Replacement
385	Q3 2021	ANHYDROUS DEXTROSE	INTRAVENOUS	INJECTION	2000.00 mg		MDE Replacement
385	Q4 2021	ANHYDROUS DEXTROSE	INTRAVENOUS	INJECTION		2700 mg	MDE Replacement
388	Q3 2021	ANHYDROUS DEXTROSE	NASAL	SPRAY, METERED	50.00 mg		MDE Replacement
388	Q4 2021	ANHYDROUS DEXTROSE	NASAL	SPRAY, METERED		200 mg	MDE Replacement
389	Q3 2021	ANHYDROUS DEXTROSE	ORAL	GRANULE, FOR SUSPENSION	2813.00 mg		MDE Replacement
389	Q4 2021	ANHYDROUS DEXTROSE	ORAL	GRANULE, FOR SUSPENSION		16878 mg	MDE Replacement
391	Q3 2021	ANHYDROUS DEXTROSE	ORAL	TABLET, EXTENDED RELEASE	15.00 mg		MDE Replacement
391	Q4 2021	ANHYDROUS DEXTROSE	ORAL	TABLET, EXTENDED RELEASE		30 mg	MDE Replacement
396	Q3 2021	ANHYDROUS DIBASIC CALCIUM PHOSPHATE	ORAL	CAPSULE, DELAYED RELEASE	381.00 mg		MDE Replacement
396	Q4 2021	ANHYDROUS DIBASIC CALCIUM PHOSPHATE	ORAL	CAPSULE, DELAYED RELEASE		381 mg	MDE Replacement
406	Q3 2021	ANHYDROUS DIBASIC CALCIUM PHOSPHATE	ORAL	TABLET, FOR SUSPENSION	101.50 mg		MDE Replacement
406	Q4 2021	ANHYDROUS DIBASIC CALCIUM PHOSPHATE	ORAL	TABLET, FOR SUSPENSION		406 mg	MDE Replacement
407	Q3 2021	ANHYDROUS DIBASIC CALCIUM PHOSPHATE	SUBLINGUAL	POWDER	10.00 mg		MDE Replacement
407	Q4 2021	ANHYDROUS DIBASIC CALCIUM PHOSPHATE	SUBLINGUAL	POWDER		30 mg	MDE Replacement
427	Q3 2021	ANHYDROUS LACTOSE	ORAL	TABLET, FILM COATED	622.21 mg		MDE Replacement
427	Q4 2021	ANHYDROUS LACTOSE	ORAL	TABLET, FILM COATED		622.21 mg	MDE Replacement
504	Q3 2021	ASCORBIC ACID	ORAL	CAPSULE, EXTENDED RELEASE	0.40 mg		MDE Replacement
504	Q4 2021	ASCORBIC ACID	ORAL	CAPSULE, EXTENDED RELEASE		0.8 mg	MDE Replacement
506	Q3 2021	ASCORBIC ACID	ORAL	POWDER, FOR SOLUTION	200.00 mg		MDE Replacement
506	Q4 2021	ASCORBIC ACID	ORAL	POWDER, FOR SOLUTION		560 mg	MDE Replacement
540	Q3 2021	ASPARTAME	ORAL	TABLET, CHEWABLE, EXTENDED RELEASE	12.00 mg		MDE Replacement
540	Q4 2021	ASPARTAME	ORAL	TABLET, CHEWABLE, EXTENDED RELEASE		18 mg	MDE Replacement
542	Q3 2021	ASPARTAME	ORAL	TABLET, FOR SUSPENSION	3.70 mg		MDE Replacement
542	Q4 2021	ASPARTAME	ORAL	TABLET, FOR SUSPENSION		14.8 mg	MDE Replacement
127	Q4 2021	ACETYLTRIBUTYL CITRATE	TOPICAL	SPONGE	5.40 %w/w		Deletion
448	Q4 2021	ANHYDROUS TRISODIUM CITRATE	ORAL	SYRUP	7.95 mg/ 5.00 ml		Deletion

FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly

Data Through: September 30, 2021
Database Last Updated: October 21, 2021